LETTER TO THE EDITOR

Evaluation of retinal microvascular perfusion in hereditary angioedema: a case-control study

Paola Triggianese1*, Massimo Cesareo2†, Maria Domenica Guarino1, Paola Conigliaro1, Maria Sole Chimenti1, Francesca Cedola1, Caterina Mazzeo2, Carlo Nucci2 and Roberto Perricone1

Abstract
Evidence supports that hereditary angioedema (HAE) may be considered as a paroxysmal permeability disorder with defective but self-limiting endothelial barrier dysfunction. A potential subclinical abnormal vascular permeability at retinal capillaries could induce damage resulting in retinopathy. We aimed at exploring for the first time the presence of microangiopathy at retinal level from a highly selective cohort of patients with HAE due to C1 esterase inhibitor protein (C1INH) deficiency (type I). We conducted a pilot, prospective, case-control study including 20 type I HAE patients and 20 age−/sex-matched healthy controls (HC). All participants underwent standard ophthalmological examination including visual fields. Superficial and deep capillary plexi in the retina were analyzed by using new optical coherence tomography angiography (OCT-A). A total of 40 eyes from 20 HAE patients and 20 eyes from HC were evaluated. Perimetric indices of visual field were slightly worse in HAE than in controls. OCT-angiograms documented in HAE patients a lower retinal capillary density in both superficial and deep scans and a higher retinal thickness compared to healthy eyes. Our findings firstly documented subclinical abnormalities in retinal microvascular network in type I HAE patients that might be associated with early subtle functional changes. This preliminary evidence supports the hypothesis of a recurrent endothelial barrier failure at retinal level in HAE patients potentially resulting in chronic damage.

Keywords: Capillaries, Complement system, Hereditary angioedema, Optical coherence tomography angiography, Retina

Background
Hereditary angioedema (HAE) due to C1 esterase inhibitor protein (C1INH) deficiency (type I HAE) is a rare disorder that is characterized by widely variable and potentially fatal attacks of subcutaneous and submucosal edema [1, 2]. Evidence supports that the contact activation resulting in the increase of vascular permeability during HAE attack is both a systemic and a local process at the affected tissues [3]. Accordingly, HAE may be considered as a paroxysmal permeability disorder with defective but self-limiting endothelial barrier dysfunction induced by a long list of mediators [4]. Angiopoietins and Vascular Endothelial Growth Factors (VEGFs) have been implicated in endothelial barrier failure in HAE as observed in diseases associated with higher vascular permeability (e.g., systemic capillary leak syndrome) [4–6]. As known, kinins play a primary role in the development of retinopathy through inflammatory mechanisms and enhanced vascular permeability that can be explained by an increase in bradykinin levels [7, 8]. In this context, the analysis of increased vascular permeability in retina might be a reasonable tool to explore vasoregulatory aspects of HAE due to C1INH deficiency. Optical Coherent Tomography Angiography (OCT-A) is a non-invasive imaging technique that is able to visualize the retinal microvasculature detecting blood flow without intravenous dye injection [9, 10].

We conducted a pilot, prospective, case-control study in order to explore for the first time the presence of a subclinical microangiopathy at retinal level from a highly selective cohort of type I HAE patients by using OCT-A.
Patients and methods
We enrolled 20 type I HAE patients referring to our tertiary center for HAE (“Policlinico Tor Vergata”, Rome, Italy) during a 3-month period (May–July 2018). Inclusion criteria were: 1) diagnosis of type I HAE [1, 2]; 2) age ≥ 18 ≤ 75 years old; 3) intraocular pressure (IOP) < 21 mmHg; 4) best-corrected visual acuity (BCVA) ≥ 0.5 LogMAR; 5) spherical equivalent refractive error between − 6.0/+ 4.0 diopters; 6) open anterior chamber angle on slit-lamp examination [11, 12]. Exclusion criteria were: 1) established primary ocular diseases; 2) systemic disorders including hypertension and/or treatments that may affect retinal function; 3) pregnancy or lactation; 4) neoplasia [11, 12]. The control group consisted of 20 (normal) subjects of the same age range and sex as the HAE patients recruited at the Ophthalmology Clinic (“Policlinico Tor Vergata”, Rome, Italy). Both eyes of each control were evaluated, however only one eye was randomly chosen for statistical analysis. The same exclusion criteria were applied to the control group.

The study described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans (updated 2008). Written informed consent was obtained from patients and controls and the study was approved by the local ethic (“Policlinico Tor Vergata”, Rome, Italy). At the enrollment, clinical records of 20 patients were registered from all HAE patients including family history, HAE disease duration, sites and severity of attacks, time interval between the last attack and the visit, concomitant disorders, on-demand and prophylactic HAE treatment. From each patient, laboratory assays were performed on the same day of the ophthalmological examination at the laboratory of the “Policlinico Tor Vergata” (Rome, Italy) and included measurements of serum C3, C4, antigentic and functional C1INH, and C1q levels (see Additional file 1) [2, 13]. Systolic and diastolic blood pressure was measured, and the derived mean arterial blood pressure (MABP) was assessed from all the subjects in the study [14, 15].

All subjects underwent a standard ophthalmological examination, including best-corrected visual acuity (BCVA), intraocular pressure (IOP), and visual field test (VF).

BCVA was measured using a standard LogMAR eye chart according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol: low vision is defined as a best-corrected visual acuity worse than 0.5 LogMAR [16]. IOP was measured by using Goldmann applanation tonometry by estimating the force (mmHg) required to applanate a constant area of the cornea [17]. Visual field defects were assessed using Humphrey Field Analyzer (HFA; model 750, Zeiss Humphrey Systems, Dublin, CA, USA), using the SITA-Standard program 30–2. Mean deviation (MD), pattern standard deviation (PSD), and visual field indexes (VFI) were calculated separately for each eye and compared between groups [18]. All the eyes were examined by means of a 6 × 6 mm optical coherence tomography angiography (OCT-A) scans (Optovue XR Avanti, Fremont, CA) [9]. Split-spectrum amplitude-decorrelation angiography generated OCT-angigrams of both superficial and deep retinal capillary plexi referred to the whole image, foveal, and parafoveal zone. The default en face display slab definition was 3 μm below the inner limiting membrane (ILM) to 15 μm below the inner plexiform layer (IPL) for the superficial capillary plexus, and 15 μm to 70 μm below the IPL for the deep capillary plexus [19, 20]. The segmentation software automatically detected the boundaries of the retinal layers from the structural OCT cross-sectional images. Retinal layer segmentation was checked for artifacts by the same experienced operator. Only images with quality > 8 have been considered for the study. It was not necessary to perform manual corrections; the Optovue XR Avanti (Fremont, CA) has active motion-tracking capability to minimize motion artifacts [21]. The OCT-A measurements were performed at the same time of the day (specifically, 3:00–5:00 pm) in both patients and controls [14, 22–24]. Thicknesses at the whole image, foveal, and parafoveal zone were measured by OCT [9, 10, 25].

Normally distributed variables were expressed by mean and standard deviation (SD). Continuous variables were compared using the parametric unpaired T test or the nonparametric Mann–Whitney U test when appropriate. The significance of any correlation was determined by Pearson correlation test. A sample size calculation was performed: the power analysis reached a value of 99% by using 2 groups of 20 subjects each one (20 cases and 20 controls) with an error α = 0.05 and an error β = 0.1. P values < 0.05 were considered significant (GraphPad Prism version 7; software for Power Analysis and Sample Size: NCSS 12 and PASS 16).

Results and discussion
A total of 40 eyes of 20 type I HAE patients (50% female) from 12 independent families were included: the confirmation of the inheritance was based mainly on the family history, and genetic testing was conducted on 12 cases [26]. Demographic and clinical data from the study population were described in Table 1.

HAE patients showed a median MD value lower than the controls (Table 1). In addition, the median PSD from HAE patients was higher than the controls.
Summarizing our findings, in HAE patients, we might assume that a subclinical edema formation increases the thickness of the parafoveal area and leads to a “relative” reduction of the vascular network by compressing the existing capillaries \[27, 28\]. The significant reduction in vessel density values that was detected in HAE cohort looks like the low vessel density documented in patients with papilledema and pseudopapilledema in whom hypothetically the apparent reduced density of vessels on OCT-A might be due to slow flow resulting from compression/stasis \[28, 29\]. In this view, in C1INH deficiency-HAE the endothelial barrier failure with enhanced vascular permeability can likely involve tissues and organs at the site of attacks \[3\]. However, this conceivable subclinical edema at retinal level may lead to a chronic damage resulting in early subtle functional changes like anomalies in perimetric indices documented in our cohort. Mild visual field defects documented in HAE patients may have been for a long time undetected because of insufficient eye examination. To date, there is a paucity of recommendations that reliably detect retinal involvement in HAE: specifically, only for HAE patients undergoing prophylactic antifibrinolytic treatment, annual ophthalmologic examinations are recommended \[30\].

As a remark, no significant correlations between OCT-A parameters and complement components levels occurred. Anyway, our data cannot exclude definitely the potential correlations between complement levels and retinal microvasculature because HAE patients have not been evaluated during an acute attack and both prophylactic and on-demand treatment likely affect circulating complement levels as well as the disease course \[2\]. Accordingly, no significant correlations occurred between OCT-A findings and number or severity of attacks in our cohort. Furthermore, when stratifying patients in accordance with danazol treatment, four patients were on long-term therapy at the time of the study while eight had a history of a previous danazol long-term prophylaxis (the mean danazol-free period at the enrollment was 7 ± 3 years). We did not register differences in the capillary density scans and in the retinal thickness by OCT-A between patients who have been on danazol \((n = 12)\) and patients never taking danazol \((n = 8)\). In addition, we did not register differences in the capillary density scans and in the retinal thickness by OCT-A between patients taking C1INH replacement therapy \((n = 9)\) and patients who did not take it \((n = 11)\) in the last 3 months.

Further investigations including a larger HAE cohort might lead to an improvement of the analysis by comparing among subgroups of patients \(e.g.,\) between patients currently taking androgens and having ever taken androgens, as well as patients experiencing treated vs.

**Table 1** Data from the study population

|                  | HAE \((n = 20)\) | HC \((n = 20)\) |
|------------------|-----------------|----------------|
| Age (years)      | 41.3 ± 13.5     | 45 ± 13        |
| Female sex (N/%) | 10/50           | 11/55          |
| HAE disease duration (years) | 27.4 ± 14     | N.A.          |
| Number of attacks \(^a\) | 8 ± 7.6       | N.A.          |
| Attack-free period (days) \(^b\) | 59 ± 71       | N.A.          |
| Danazol prophylaxis (N/%) | 4/20         | N.A.          |
| C4 (mg/dl)       | 9.5 ± 4.5       | N.A.          |
| Clq (mg/l)       | 146 ± 20.3      | N.A.          |
| C1INH (mg/dl)    | 7 ± 3.4         | N.A.          |
| MABP (mmHg)      | 89 ± 10.4       | 88 ± 8        |
| BCVA (LogMAR)    | 0.01 ± 0.1 \(R\); 0.01 ± 0.1 \(L\) | 0.013 ± 0.03 |
| IOP (mmHg)       | 16.5 ± 3 \(R\); 16.7 ± 2.9 \(L\) | 16 ± 3        |
| MD (median, dB)  | −1.9 **(R); −2 ***(L) | 0.3          |
| PSD (median, dB) | 2.16 **(R); 1.9 *(L) | 1.6          |
| VFI (range %)    | 92–98           | 98–100        |

HAE hereditary angioedema, HC healthy controls, C1INH C1 inhibitor, MABP mean arterial blood pressure, BCVA best corrected visual acuity, IOP intraocular pressure, MD mean deviation, PSD Pattern Standard Deviation, VFI visual field index, \(R\) right eyes, \(L\) left eyes. Continuous variables were shown using mean and standard deviation (SD) while categorical variables with absolute frequencies and percentages. Values from patients were compared with controls using the parametric unpaired T test or the nonparametric Mann–Whitney U test when appropriate and \(P\) values < 0.05 were considered significant \((p < 0.05, **p < 0.01, ***p < 0.001, \text{with the respect to control eyes})\).

\(^a\)number of HAE attacks in the last 12 months; \(^b\)number of days from the last acute attack to the time of the visit.
Fig. 1 (See legend on next page.)
untreated attacks). In addition, future studies on structural analysis of the retina are certainly awaited [29, 31].

Our pilot proof-of-concept study for the first time provided evidence of retinal microcirculatory abnormalities in HAE patients: these early microvascular changes revealed by OCT-A could precede clinical neuro-retinopathies.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13023-019-1263-6.

Additional file 1. Immunologic assessment. Table S1. Optical coherence tomography angiography findings from the study population. Figure S1. Representative 3 × 3-mm angiograms of retinal imaging on optical coherence tomography angiography.

Abbreviations
BCVA: Best corrected visual acuity; C1INH: C1 inhibitor; HAE: Hereditary angioedema; HC: Healthy controls; IOP: Intraocular pressure; MD: Mean deviation; OCT-A: Optical coherence tomography angiography; PSD: Pattern standard deviation; VEGF: Vascular Endothelial Growth Factors; VFI: Visual field index

Acknowledgements
We are thankful to the patients for being part of this study.

Authors’ contributions
PT and MC designed the study and wrote the manuscript. MDG and FC performed the analysis of the HAE disease. MC and CM performed the ophthalmological examination. MC and CN analyzed and interpreted the data regarding the ophthalmological examination. PT, PC, and MSC registered and analyzed all the laboratory and ophthalmological findings. MC and RP read and approved the final manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans (updated 2008). Written informed consent was obtained from patients and controls and the study was approved by the local ethic (“Policlinico Tor Vergata”, Rome, Italy).

Consent for publication
The consent for publication has been obtained from subjects.

Competing interests
The authors declare that they have no competing interests.

Author details
1Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy. 2Ophthalmology Unit, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.

Received: 29 March 2019 Accepted: 22 November 2019

References
1. Maurer M, Nagerl M, Anstochegi I, Aygören-Pürsün E, Betschei S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-the 2017 revision and update. Allergy. 2018;73:1575–96.
2. Triggianese P, Guarino MD, Pellicano C, Bozì M, Greco E, Modica S, et al. Recurrent angioedema: occurrence, features, and concomitant diseases in an Italian single-center study. Int Arch Allergy Immunol. 2017;172:55–63.
3. Hofman ZL, Relan A, Hack CE. Hereditary angioedema attacks: local swelling at multiple sites. Clin Rev Allergy Immunol. 2016;50:34–40.
4. Loffredo S, Bova M, Sulfritti C, Borrelli F, Zanchelli A, Petraroli A, et al. Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema. Allergy. 2016;71:989–96.
5. Colombo R, Wu MA, Catena E, Perotti A, Fossali T, Gelli F, et al. The role of failing autonomic nervous system on life-threatening idiopathic systemic capillary leak syndrome. Front Med (Lausanne). 2018;5:111.
6. Xie Z, Ghosh CC, Patel R, Iwaki S, Gaskins D, Nelson C, et al. Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood. 2012;119:4321–32.
7. Abdulali M, Haddad NM, Sun JK, Silva PS. The role of plasma Kallikrein-Kinin pathway in the development of diabetic retinopathy: pathophysiology and therapeutic approaches. Semin Ophthalmol. 2016;31:19–24.
8. Edalati K, Roest MT, Buchanan ML, Teeter M, Maberly DA. Central serous chorioretinopathy and idiopathic non-histaminergic angioedema. Can J Ophthalmol. 2009;44:606–7.
9. Conigliaro P, Cesareo M, Chimenti MS, Triggianese P, Canofari C, Aloe G, et al. Evaluation of retinal microvascular density in patients affected by systemic lupus erythematosus: an optical coherence tomography angiography study. Ann Rheum Dis. 2019;78:287–9.
10. Roth R, Rommel F, Klapp S, Humrich JR, Nieberding R, Lange T, et al. Evaluation of retinal microvascular perfusion in systemic sclerosis: a case-control study. Ann Rheum Dis. 2019;78:857–8.
11. Conigliaro P, Triggianese P, Draghessi G, Canofari C, Aloe G, Chimenti MS, et al. Evidence for the detection of subclinical retinal involvement in systemic lupus Erythematosus and Sjögren syndrome: a potential association with therapies. Int Arch Allergy Immunol. 2018;177:45–56.
12. Cesareo M, Ciuffoletti E, Martucci A, Sebastiani J, Sorge RP, Lamantea E, et al. Assessment of the retinal posterior pole in dominant optic atrophy by spectral-domain optical coherence tomography and microperimetry. PLoS One. 2017;12:e0174560.
13. Triggianese P, Chimenti MS, Touti E, Ballanti E, Guarino MD, Perricone C, Perricone R. The autoimmune side of hereditary angioedema: insights on the pathogenesis. Autoimmun Rev. 2015;14:665–9.
14. Singh SR, Rasheed MA, Goud A, Sahoo NK, Yuppaparoba KK, Chhablani J. Diurnal variation in subfoveal and peripapillary choroidal vascularity index in healthy eyes. Indian J Ophthalmol. 2019;67:1667–72.
15. Moran D, Epstein Y, Keren G, Laor A, Sherez J, Shapiro Y. Calculation of mean arterial pressure during exercise as a function of heart rate. Appl Hum Sci. 1995;14:293–5.

16. Jonas JB, Bergua A, Schmitz-Valckenberg P, Papastathopoulos KI, Budde WM. Ranking of optic disc variables for detection of glaucomatous optic nerve damage. Invest Ophthalmol Vis Sci. 2000;41:1764–73.

17. Kouchaki B, Hashemi H, Yekta A, Khabadkhoo M. Comparison of current tonometry techniques in measurement of intraocular pressure. J Curr Ophthalmol. 2016;29:92–7.

18. Birt CM, Shin DH, Samudrala V, Hughes BA, Kim C, Lee D. Analysis of reliability indices from Humphrey visual field tests in an urban glaucoma population. Ophthalmology. 1997;104:1126–30.

19. Rommel F, Siegfried F, Kurz M, Brinkmann MP, Rothe M, Rudolf M, et al. Impact of correct anatomical slab segmentation on foveal avascular zone measurements by optical coherence tomography angiography in healthy adults. J Curr Ophthalmol. 2018;30:156–60.

20. Spaide RF, Curcio CA. Evaluation of segmentation of the superficial and deep vascular layers of the retina by optical coherence tomography angiography instruments in Normal eyes. JAMA Ophthalmol. 2017;135:259–62.

21. Lauermann JL, Woetzel AK, Treder M, Alnawaiseh M, Clemens CR, Eter N, et al. Prevalences of segmentation errors and motion artifacts in OCT-angiography differ among retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2018;256:1807–16.

22. Siegfried F, Rommel F, Rothe M, Brinkmann MP, JAM S, Freitag J, et al. Evaluating diurnal changes in choroidal sublayer perfusion using optical coherence tomography angiography. Acta Ophthalmol. 2019;97:e1062-e1068.

23. Rommel F, Siegfried F, Sochurek JAM, Rothe M, Brinkmann MP, Kurz M, et al. Mapping diurnal variations in choroidal sublayer perfusion in patients with idiopathic epiretinal membrane: an optical coherence tomography angiography study. Int J Retina Vitreous. 2019;5:12.

24. Sarwar S, Hassan M, Soliman MK, Halim MS, Sadiq MA, Afridi R, et al. Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography. Int J Retina Vitreous. 2019;4:37.

25. Samara WA, Shahlaee A, Adam MK, Khan MA, Chiang A, Maguire JJ, Hsu J, Ho AC. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. Ophthalmology. 2017;124:235–44.

26. Guarino MD, Perricone C, Guarino S, Gambardella S, D’Apice MR, Fontana L, et al. Denaturing HPLC in laboratory diagnosis of hereditary angioedema. J Allergy Clin Immunol. 2007;120:962–5.

27. Bosma EK, van Noorden CJF, Schlingemann RO, Klaassen I. The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema. Fluids Barriers CNS. 2018;15:24.

28. Cunha-Vaz J. Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown. Dev Ophthalmol. 2017;58:11–20.

29. Fard MA, Sahralyana A, Jali J, Hejaz M, Suwan Y, Ritch R, Subramanian PS. Optical coherence tomography angiography in papilledema compared with pseudopapilledema. Invest Ophthalmol Vis Sci. 2019;60:169–75.

30. Caballero T, Baeza ML, Cañabate R, Campos A, Cimbollek S, Gómez-Traceira C, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Invest Allergol Clin Immunol. 2011;21:422–41.

31. Perricone C, Agram-Levin N, Shoenfeld N, de Carolis C, Guarino MD, Gigliucci G, et al. Evidence of impaired sense of smell in hereditary angioedema. Allergy. 2011;66:140–54.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions